1. Academic Validation
  2. 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses

20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses

  • Biochem Pharmacol. 1991 Sep 27;42(8):1569-75. doi: 10.1016/0006-2952(91)90426-6.
L Binderup 1 S Latini E Binderup C Bretting M Calverley K Hansen
Affiliations

Affiliation

  • 1 Department of Biology, Leo Pharmaceutical Products, Ballerup, Denmark.
Abstract

The 20-epi-vitamin D3 analogues are a novel class of vitamin D3 derivatives, structurally related to 1 alpha,25-dihydroxycholecalciferol (1 alpha,25(OH)2D3). They are characterized by an altered stereochemistry at carbon 20 in the side-chain. In vitro, these new analogues were found to be considerably more potent as regulators of growth and differentiation in the human histiocytic lymphoma cell line U 937 than 1 alpha,25(OH)2D3, despite a practically unchanged calcemic activity in vivo. The most potent analogue, KH 1060, inhibited cell proliferation by 50% at 10(-12) M (14,000 times more active than 1 alpha,25(OH)2D3). At the same time, KH 1060 induced cell differentiation at concentrations as low as 10(-14)M. In addition, the 20-epi-vitamin D3 analogues were found to be very potent inhibitors of T-lymphocyte proliferation induced by interleukin-1 or alloantigen. In this respect, they were several orders of magnitude more active than the potent immunosuppressive agent cyclosporin A (CyA). KH 1060, the most potent analogue, inhibited interleukin-1-induced mouse thymocyte proliferation by 50% at 3 x 10(-16) M and allogeneic stimulation of mouse spleen lymphocytes at 5 x 10(15) M. These effects were considered to be mediated by inhibition of interleukin-2 release from activated T-lymphocytes. The new analogues are of potential interest in the prevention of graft rejection and in the treatment of psoriasis, Cancer and auto-immune diseases.

Figures
Products